Abstract 11455: Outcomes of Latent Rheumatic Heart Disease: External Validation of a Simplified Score in Patients With And Without Secondary Prophylaxis

医学 内科学 人口 心脏病 随机对照试验 二尖瓣 儿科 外科 心脏病学 环境卫生
作者
Bruno Ramos Nascimento,Maria Carmo Pereira Nunes,José Luiz Padilha da Silva,Andrew C. Steer,Daniel Engelman,Emmy Okello,Jafesi Pulle,Joselyn Rwebembera,Liesl Zühlke,Mariana Mirabel,Miriam Nakitto,Rachel Sarnacki,Craig Sable,Andrea Beaton
出处
期刊:Circulation [Ovid Technologies (Wolters Kluwer)]
卷期号:146 (Suppl_1)
标识
DOI:10.1161/circ.146.suppl_1.11455
摘要

Background: Secondary antibiotic prophylaxis reduces progression in children with latent rheumatic heart disease (RHD). However, nearly half of children show improvement with or without prophylaxis. Improved risk stratification could refine prophylaxis recommendations following positive screening echo. We aimed to validate a previously developed echo risk score to predict mid-term RHD outcomes among children with latent RHD. Methods: Our population included children who completed the GOAL Trial, a randomized controlled trial of secondary antibiotic prophylaxis among children with latent RHD in Uganda. These children underwent echo at enrollment and study completion, with rigorous blinded adjudication by a 4-member panel to establish diagnosis. We applied a point-based risk score developed from prior Brazilian and Ugandan cohorts, consisting of 5 variables (mitral valve (MV) anterior leaflet thickening (3 points), MV excessive leaflet tip motion (3), MV regurgitation jet length ≥2 cm (6), aortic valve focal thickening (4) and any aortic regurgitation (5)) to predict unfavorable outcome, defined as progression of diagnostic category (borderline to definite, definite mild valvular disease to definite moderate/severe disease) or remaining with definite RHD. Results: At total 801 patients (626 borderline and 175 definite RHD, mean age 12.5±2.9 years) were included, with median follow-up of 24 months. RHD progression was observed in 3 patients in the Penicillin group, vs. 33 in the control group, and overall, 386 patients regressed and 377 remained stable. The echo score was strongly associated with unfavorable outcome (OR: 1.25, 95% CI 1.15 - 1.36, p<0.001). Unfavorable outcome rates in low (≤6 points), intermediate (7 - 9) and high-risk (≥10) children at follow-up were 12.2%, 31.1%, and 42.2%, (p<0.001) respectively, with area under the ROC curve of 0.64 (95% CI 0.59 - 0.69). Among children without prophylaxis, the score had a similarly good performance: OR: 1.24 (95% CI 1.12 - 1.39), area under the ROC curve: 0.64 (95% CI 0.58 - 0.70). Conclusions: The simple risk score provided an accurate prediction of RHD status at 2-years, showing a good performance in a population with milder RHD phenotypes, with a potential value for global risk stratification.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
墨墨小7发布了新的文献求助10
2秒前
来者完成签到,获得积分10
3秒前
传奇3应助科研通管家采纳,获得10
4秒前
大个应助科研通管家采纳,获得10
4秒前
科研通AI5应助科研通管家采纳,获得20
4秒前
ding应助科研通管家采纳,获得10
4秒前
搜集达人应助科研通管家采纳,获得10
4秒前
iNk应助科研通管家采纳,获得10
5秒前
Xiaoxiao应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
上官若男应助科研通管家采纳,获得10
5秒前
5秒前
6秒前
充电宝应助qin采纳,获得30
6秒前
Lric完成签到,获得积分10
7秒前
sjr123发布了新的文献求助20
7秒前
健壮的半青完成签到 ,获得积分10
7秒前
7秒前
orixero应助纯真的晓啸采纳,获得10
9秒前
共享精神应助骄傲yy采纳,获得30
9秒前
11秒前
ssx完成签到,获得积分10
11秒前
心若向阳完成签到,获得积分10
11秒前
12秒前
绝尘发布了新的文献求助10
12秒前
哦啦啦发布了新的文献求助10
16秒前
17秒前
17秒前
JamesPei应助小李采纳,获得10
18秒前
河神发布了新的文献求助10
18秒前
科研通AI2S应助Cassiel采纳,获得30
20秒前
21秒前
多金完成签到,获得积分10
22秒前
榴莲完成签到,获得积分10
23秒前
敬老院1号完成签到,获得积分0
23秒前
研友_nqa9Kn发布了新的文献求助10
25秒前
25秒前
河神完成签到,获得积分10
26秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
1.3μm GaAs基InAs量子点材料生长及器件应用 1000
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3526144
求助须知:如何正确求助?哪些是违规求助? 3106527
关于积分的说明 9280744
捐赠科研通 2804127
什么是DOI,文献DOI怎么找? 1539278
邀请新用户注册赠送积分活动 716514
科研通“疑难数据库(出版商)”最低求助积分说明 709495